# A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials

> **NCT02187107** · PHASE2 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 52 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** TMC114
- **DRUG:** rtv

## Key facts

- **NCT ID:** NCT02187107
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2005-09
- **Final completion:** 2009-03
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2014-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02187107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02187107, "A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02187107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*